India · Delayed Price · Currency is INR Mono Pharmacare Statistics
Total Valuation
Mono Pharmacare has a market cap or net worth of INR 157.25 million. The enterprise value is 712.78 million.
| Market Cap | 157.25M |
| Enterprise Value | 712.78M |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mono Pharmacare has 17.67 million shares outstanding.
| Current Share Class | 17.67M |
| Shares Outstanding | 17.67M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -27.62% |
| Owned by Insiders (%) | 56.72% |
| Owned by Institutions (%) | n/a |
| Float | 7.65M |
Valuation Ratios
The trailing PE ratio is 21.71.
| PE Ratio | 21.71 |
| Forward PE | n/a |
| PS Ratio | 0.09 |
| PB Ratio | 0.49 |
| P/TBV Ratio | 0.49 |
| P/FCF Ratio | 5.89 |
| P/OCF Ratio | 5.88 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.78, with an EV/FCF ratio of 26.68.
| EV / Earnings | 97.31 |
| EV / Sales | 0.43 |
| EV / EBITDA | 15.78 |
| EV / EBIT | 16.19 |
| EV / FCF | 26.68 |
Financial Position
The company has a current ratio of 1.91, with a Debt / Equity ratio of 1.77.
| Current Ratio | 1.91 |
| Quick Ratio | 1.20 |
| Debt / Equity | 1.77 |
| Debt / EBITDA | 12.51 |
| Debt / FCF | 21.15 |
| Interest Coverage | 1.47 |
Financial Efficiency
Return on equity (ROE) is 2.32% and return on invested capital (ROIC) is 3.40%.
| Return on Equity (ROE) | 2.32% |
| Return on Assets (ROA) | 2.37% |
| Return on Invested Capital (ROIC) | 3.40% |
| Return on Capital Employed (ROCE) | 7.47% |
| Weighted Average Cost of Capital (WACC) | 3.39% |
| Revenue Per Employee | 25.89M |
| Profits Per Employee | 114,453 |
| Employee Count | 64 |
| Asset Turnover | 1.43 |
| Inventory Turnover | 3.21 |
Taxes
In the past 12 months, Mono Pharmacare has paid 3.51 million in taxes.
| Income Tax | 3.51M |
| Effective Tax Rate | 32.40% |
Stock Price Statistics
The stock price has decreased by -60.96% in the last 52 weeks. The beta is -0.29, so Mono Pharmacare's price volatility has been lower than the market average.
| Beta (5Y) | -0.29 |
| 52-Week Price Change | -60.96% |
| 50-Day Moving Average | 9.24 |
| 200-Day Moving Average | 14.60 |
| Relative Strength Index (RSI) | 51.87 |
| Average Volume (20 Days) | 8,300 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mono Pharmacare had revenue of INR 1.66 billion and earned 7.33 million in profits. Earnings per share was 0.41.
| Revenue | 1.66B |
| Gross Profit | 88.34M |
| Operating Income | 44.02M |
| Pretax Income | 10.84M |
| Net Income | 7.33M |
| EBITDA | 45.16M |
| EBIT | 44.02M |
| Earnings Per Share (EPS) | 0.41 |
Balance Sheet
The company has 9.84 million in cash and 565.02 million in debt, with a net cash position of -555.18 million or -31.42 per share.
| Cash & Cash Equivalents | 9.84M |
| Total Debt | 565.02M |
| Net Cash | -555.18M |
| Net Cash Per Share | -31.42 |
| Equity (Book Value) | 319.67M |
| Book Value Per Share | 18.07 |
| Working Capital | 579.53M |
Cash Flow
In the last 12 months, operating cash flow was 26.76 million and capital expenditures -45,000, giving a free cash flow of 26.72 million.
| Operating Cash Flow | 26.76M |
| Capital Expenditures | -45,000 |
| Depreciation & Amortization | 1.14M |
| Net Borrowing | 12.72M |
| Free Cash Flow | 26.72M |
| FCF Per Share | 1.51 |
Margins
Gross margin is 5.33%, with operating and profit margins of 2.66% and 0.44%.
| Gross Margin | 5.33% |
| Operating Margin | 2.66% |
| Pretax Margin | 0.65% |
| Profit Margin | 0.44% |
| EBITDA Margin | 2.73% |
| EBIT Margin | 2.66% |
| FCF Margin | 1.61% |
Dividends & Yields
Mono Pharmacare does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 4.66% |
| FCF Yield | 16.99% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Mono Pharmacare has an Altman Z-Score of 2.36 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.36 |
| Piotroski F-Score | 4 |